New insights into schizophrenia disease genes interactome in the human brain: Emerging targets and therapeutic implications in the postgenomics era

OMICS A Journal of Integrative Biology

Volumn 18, Issue 12, 2014, Pages 754-766

  Podder, Avijit ^a   Latha, Narayanan ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATAXIN 1; BROMOCRIPTINE; FLUPHENAZINE; HALOPERIDOL; HEAT SHOCK COGNATE PROTEIN 70; LURASIDONE; TRAZODONE; TRIFLUOPERAZINE; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; BRAIN REGION; BRAIN TISSUE; GENE EXPRESSION; GENE INTERACTION; GENOMICS; HOUSEKEEPING GENE; HUMAN; HYPOTHALAMUS; MOLECULAR DOCKING; PHENOTYPE; SCHIZOPHRENIA; TISSUE SPECIFICITY; BRAIN; FACTUAL DATABASE; GENETIC PREDISPOSITION; GENETICS; METABOLISM;

BRAIN; DATABASES, FACTUAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PROTEIN BINDING; SCHIZOPHRENIA;

EID: 84919384821     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2014.0082     Document Type: Article

References (94)

1. Abi-Dargham A. (2004). Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsy-chopharmacol 1, S1-S5.
2. Aerts S, Lambrechts D, Maity S, et al. (2006). Gene prioritization through genomic data fusion. Nat Biotechnol 24, 537-544.
3. Amberger J, Bocchini CA, Scott AF, and Hamosh A. (2009). McKusick's Online Mendelian Inheritance in Man (OMIM). Nucleic Acids Res 37, D793-D796.
4. Andreasen NC, Arndt S, Swayze V, et al. (1994). Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 266, 294-298.
5. Andreasen NC, Ehrhardt JC, Swayze VW, et al. (1990). Magnetic resonance imaging of the brain in schizophrenia: The pathophysiologic significance of structural abnormalities. Arch Gen Psychiatry 47, 35-44.
6. Aperia A, and Greengard P. (2006). Dopamine receptor response to NMDA stimulation. Am J Psychiatry 163, 1682-1682.
7. Assenov Y, Ramirez F, Schelhorn SE, Lengauer T, and Al-brecht M. (2008). Computing topological parameters of biological networks. Bioinformatics 24, 282-284.
8. Badrinarayan P, and Sastry GN. (2013). Rational approaches towards lead optimization of kinase inhibitors: The issue of specificity. Curr Pharm Des 19, 4714-4738.
9. Barabasi AL, and Albert R. (1999). Emergence of scaling in random networks. Science 286, 509-512.
10. Barta PE, Pearlson GD, Powers RE, et al. (1990). Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. Am J Psychiatry 147, 1457-1462.
11. Bauer-Mehren A, Bundschus M, Rautschka M, Mayer MA, Sanz F, and Furlong LI. (2011). Gene-disease network analysis reveals functional modules in mendelian, complex and environmental diseases. PLoS One 6, e20284.
12. Bergen SE, and Petryshen TL. (2012). Genome-wide association studies of schizophrenia: Does bigger lead to better results? Curr Opin Psychiatry 25, 76-82.
13. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, and Bourne PE. (2000). The Protein Data Bank. Nucleic Acids Res 28, 235-242.
14. Bindea G, Mlecnik B, Hackl H, et al. (2009). ClueGO: A Cy-toscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25, 1091-1093.
15. Boileau I, Payer D, Chugani B, et al. (2013). In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: A positron emission tomography study with [11C]-(+)-PHNO. Mol Psychiatry. doi: 10.1038/mp.2013.163. [Epub ahead of print.]
16. Bossi A, and Lehner B. (2009). Tissue specificity and the human protein interaction network. Mol Syst Biol 5, 260.
17. Brandes U. (2001). A faster algorithm for betweenness cen-trality. J Math Sociol 25, 163-117.
18. Bühler B, Hambrecht M, Löffler W, an der Heiden W, and Häfner H. (2002). Precipitation and determination of the onset and course of schizophrenia by substance abuse: A retrospective and prospective study of 232 population-based first illness episodes. Schizophrenia Res 54, 243-252.
19. Butte AJ, Dzau VJ, and Glueck SB. (2001). Further defining housekeeping, or maintenance, genes Focus on A compendium of gene expression in normal human tissues. Physiol Genomics 7, 95-96.
20. Camargo LM, Collura V, Rain JC, Mizuguchi K, Hermjakob H, Kerrien S, Bonnert TP, Whiting PJ, and Brandon NJ. (2007). Disrupted in Schizophrenia 1 Interactome: Evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol Psychiatry 12, 74-86.
21. Carlsson M, and Carlsson A. (1990). Interactions between glutamatergic and monoaminergic systems within the basal ganglia-Implications for schizophrenia and Parkinson's disease. Trends Neurosci 13, 272-276.
22. Chang CW, Cheng WC, Chen CR, Shu WY, Tsai ML, Huang CL, and Hsu IC. (2011). Identification of human housekeeping genes and tissue-selective genes by microarray meta-analysis. PLoS One 6, e22859.
23. Cheng WC, Chang CW, Chen CR, et al. (2011). Identification of reference genes across physiological states for qRT-PCR through microarray meta-analysis. PLoS ONE 6, e17347.
24. Cohen P. (2002). Protein kinases-The major drug targets of the twenty-first century? Nat Rev Drug Discov 1, 309-315.
25. Craig J. (2008). Complex diseases: Research and applications. Nat Educ 1, 1.
26. Critchley HD, Eccles J, and Garfinkel SN. (2013). Interaction between cognition, emotion, and the autonomic nervous system. Handb Clin Neurol 117, 59-77.
27. Dezso Z, Nikolsky Y, Sviridov E, et al. (2008). A comprehensive functional analysis of tissue specificity of human gene expression. BMC Biol 6, 49.
28. Diestel R. (2005). Graph Theory. Springer-Verlag, Heidelberg. ISBN 3-540-26182-6.
29. Dingledine R, Borges K, Bowie D, et al. (1999). The glutamate receptor ion channels. Pharmacol Rev 51, 7-61.
30. Divac N, Prostran M, Jakovcevski I, and Cerovac N. (2014). Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int 2014, 656370.
31. Dixon L, Haas G, Weide PJ, Sweeney J, and Frances AJ. (1991). Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. Am J Psychiatry 148, 224-230.
32. Eisenberg E, and Levanon EY. (2013). Human housekeeping genes, revisited. Trends Genet 29, 569-574.
33. Evins AE, Green AI, Kane JM, and Murray RM. (2012). The effect of marijuana use on the risk for schizophrenia. J Clin Psychiatry 73, 1463-1468.
34. Fabi E, Fusco A, Valiante M, and Celli R. (2013). Genetics and epigenetics of schizophrenia. Clin Ter 164, e319-24.
35. Freeman LC. (1979). Centrality in social networks: Conceptual clarification. Soc Networks 1, 215-239.
36. Friesner RA, Murphy RB, Repasky MP, et al. (2006). Extra Precision Glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49, 6177-6196.
37. Gao C, and Wolf ME. (2008). Dopamine receptors regulate NMDA receptor surface expression in prefrontal cortex neurons. J Neurochem 106, 2489-2501.
38. Gilman SR, Chang J, Xu B, Bawa TS, Gogos JA, Karayiorgou M, and Vitkup D. (2012). Diverse types of genetic variation converge on functional gene networks involved in schizophrenia. Nat Neurosci 15, 1723-1728.
39. Guo AY, Sun J, Jia P, and Zhao Z. (2010). A novel microRNA and transcription factor mediated regulatory network in schizophrenia. BMC Syst Biol 4, 10.
40. Hans-Gert B, Gerburg K, Johann S, Henrik D, and Bernhard B. (2010). The hypothalamus in schizophrenia research: No longer a wallflower existence. Open Neuroendocrinol J 3, 59-67.
41. Harrison PJ, Pritchett D, Stumpenhorst K, et al. (2012). Genetic mouse models relevant to schizophrenia: Taking stock and looking forward. Neuropharmacology 62, 1164-1167.
42. Howes OD, and Kapur S. (2009). The dopamine hypothesis of schizophrenia: Version III-The final common pathway. Schizophr Bull 35, 549-562.
43. Hsu PC, Yang UC, Shih KH, Liu CM, Liu YL, and Hwu HG. (2008). A protein interaction based model for schizophrenia study. BMC Bioinformatics 9, S23.
44. Huang CH, Deng W, Chen ZF, et al. (2009). Brain structure abnormality as genetic endophenotype of schizophrenia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 26, 490-494.
45. Jacobs D, and Silverstone T. (1986). Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med 16, 323-329.
46. Janssens AC, and van Duijn CM. (2008). Genome-based prediction of common diseases: Advances and prospects. Hum Mol Genet 17, R166-173.
47. Jeong H, Mason SP, Barabasi AL, and Oltvai ZN. (2001). Lethality and centrality in protein networks. Nature 411, 41-42.
48. Jia P, Kao CF, Kuo PH, and Zhao Z. (2011). A comprehensive network and pathway analysis of candidate genes in major depressive disorder. BMC Syst Biol 23, S12.
49. Jia P, Sun J, Guo A, and Zhao Z. (2010). SZGR: A comprehensive schizophrenia gene resource. Mol Psychiatry 15, 453-462.
50. Jia P, Wang L, Fanous AH, Pato CN, Edwards TL; International Schizophrenia Consortium, and Zhao Z. (2012). Network-assisted investigation of combined causal signals from genome-wide association studies in schizophrenia. PLoS Comput Biol 8, e1002587.
51. Jiang T, Zhou Y, Liu B, Liu Y, and Song M. (2013). Brain-netome-wide association studies in schizophrenia: The advances and future. Neurosci Biobehav Rev 37, 2818-2835.
52. Kanehisa M, Goto S, Sato Y, Furumichi M, and Tanabe M. (2012). KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 40, D109-114.
53. Klomp A, Koolschijn PC, Hulshoff Pol HE, Kahn RS, and Haren NE. (2012). Hypothalamus and pituitary volume in schizophrenia: a structural MRI study. Int J Neuropsycho-pharmacol 15, 281-288.
54. Knox C, Law V, Jewison T, et al. (2011). DrugBank 3.0: A comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 39, D1035-1041.
55. Kumarasinghe N, Tooney PA, and Schall U. (2012). Finding the needle in the haystack: A review of microarray gene expression research into schizophrenia. Aust N Z J Psychiatry 46, 598-610.
56. Lau CI, Wang HC, Hsu JL, and Liu ME. (2013). Does the dopamine hypothesis explain schizophrenia? Rev Neurosci 24, 389-400.
57. Lee SA, Tsao TT, Yang KC, et al. (2011). Construction and analysis of the protein-protein interaction networks for schizophrenia, bipolar disorder, and major depression. BMC Bioinformatics 12, S20.
58. Luo X, Huang L, Jia P, Li M, Su B, Zhao Z, and Gan L. (2014). Protein-protein interaction and pathway analyses of top schizophrenia genes reveal schizophrenia susceptibility genes converge on common molecular networks and enrichment of nucleosome (chromatin) assembly genes in schizophrenia susceptibility loci. Schizophr Bull 40, 39-49.
59. McGuire JL, Hammond JH, Yates SD, Chen D, Haroutunian V, Meador-Woodruff JH, and McCullumsmith RE. (2014). Altered serine/threonine kinase activity in schizophrenia. Brain Res 1568, 42-54.
60. Morgan AA, Dudley JT, Deshpande T, and Butte AJ. (2010). Dynamism in gene expression across multiple studies. Phy-siol Genomics 40, 128-140.
61. Murray RM, Paparelli A, Morrison PD, Marconi A, and Di Forti M. (2013). What can we learn about schizophrenia from studying the human model, drug-induced psychosis? Am J Med Genet B Neuropsychiatr Genet 162B, 661-670.
62. Pelayo-Terán JM, Suárez-Pinilla P, Chadi N, and Crespo-Fa-corro B. (2012). Gene-environment interactions underlying the effect of cannabis in first episode psychosis. Curr Pharm Des 18, 5024-5035.
63. Podder A, Jatana N, and Latha N. (2014). Human Dopamine Receptors Interaction Network (DRIN): A systems biology perspective on topology, stability and functionality of the network. J Theor Biol 357, 169-183.
64. Potkin SG, Macciardi F, Guffanti G, et al. (2010). Identifying gene regulatory networks in schizophrenia. Neuroimage 53, 839-847.
65. Premkumar P, Kumari V, Corr PJ, and Sharma T. (2006). Frontal lobe volumes in schizophrenia: Effects of stage and duration of illness. J Psychiatr Res 40, 627-637.
66. Putnam DK, Sun J, and Zhao Z. (2011). Exploring schizophrenia drug-gene interactions through molecular network and pathway modeling. AMIA Annu Symp Proc 2011, 1127-1133.
67. Rabin RA, Zakzanis KK, Daskalakis ZJ, and George TP. (2013). Effects of cannabis use status on cognitive function, in males with schizophrenia. Psychiatry Res 206, 158-165.
68. Rastelli G, Del Rio A, Degliesposti G, and Sgobba M. (2010). Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA. J Comput Chem 31, 797-810.
69. Rivals I, Personnaz L, Taing L, and Potier MC. (2007). Enrichment or depletion of a GO category within a class of genes: Which test? Bioinformatics 23, 401-407.
70. Schultz SH, North SW, and Shields CG. (2007). Schizophrenia: A review. Am Fam Physician 75, 1821-1829.
71. Schwab SG, and Wildenauer DB. (2013). Genetics of psychiatric disorders in the GWAS era: An update on schizophrenia. Eur Arch Psychiatry Clin Neurosci 2, S147-154.
72. Sebat J, Levy DL, and McCarthy SE. (2009). Rare structural variants in schizophrenia: One disorder, multiple mutations; one mutation, multiple disorders. Trends Genet 25, 528-535.
73. Seeman P. (2013). Are dopamine D2 receptors out of control in psychosis?. Prog Neuropsychopharmacol Biol Psychiatry 4, 146-152.
74. Shannon P, Markiel A, Ozier O, et al. (2003). Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498-2504.
75. Singh S, Kumar A, Agarwal S, Phadke SR, and Jaiswal Y. (2014). Genetic insight of schizophrenia: Past and future perspectives. Gene 535, 97-100.
76. Sreedevi C, and Danail GB. (2012). A network view on schizophrenia related genes. Network Biol 2, 16-25.
77. Su AI, Wiltshire T, Batalov S, et al. (2004). A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci 101, 6062-6067.
78. Sun J, Jia P, Fanous AH, et al. (2010). Schizophrenia gene networks and pathways and their applications for novel candidate gene selection. PLoS One 5, e11351.
79. Sun J, Jia P, Fanous AH, et al. (2009). A multi-dimensional evidence-based candidate gene prioritization approach for complex diseases-schizophrenia as a case. Bioinformatics 25, 2595-2602.
80. Sun J, Xu H, and Zhao Z. (2012). Network-assisted investigation of antipsychotic drugs and their targets. Chem Biodivers 9, 900-910.
81. Sunday AA. (2011). Can the action of amphetamine on dopa-mine cause schizophrenia? Psychol Edu J. Vol. 39, No. 1.
82. Tognin S, Rambaldelli G, Perlini C, et al. (2012). Enlarged hypothalamic volumes in schizophrenia. Psychiatry Res 204, 75-81.
83. Torkamani A, Brian D, Nicholas JS, and Elizabeth AT. (2010). Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. Genome Res 20, 403-412.
84. Tseng KY, Lewis BL, Lipska BK, and O'Donnell P. (2007). Post-pubertal disruption of medial prefrontal cortical dopa-mine-glutamate interactions in a developmental animal model of schizophrenia. Biol Psychiatry 62, 730-738.
85. Tu PC, Lee YC, Chen YS, Li CT, and Su TP. (2013). Schizophrenia and the brain's control network: Aberrant within-and between-network connectivity of the frontoparietal network in schizophrenia. Schizophr Res 147, 339-347.
86. Van Os J, Rutten BP, and Poulton R. (2008). Gene-environment interactions in schizophrenia: Review of epidemiological findings and future directions. Schizophr Bull 34, 1066-1082.
87. Vasaikar SV, Padhi AK, Jayaram B, and Gomes J. (2013). NeuroDNet-An open source platform for constructing and analyzing neurodegenerative disease networks. BMC Neu-rosci 14, 3.
88. Vázquez A, Dobrin R, Sergi D, Eckmann JP, Oltvai ZN, and Barabási AL. (2004). The topological relationship between the large-scale attributes and local interaction patterns of complex networks. Proc Natl Acad Sci USA 101, 17940-17945.
89. Werner FM, and Covenas R. (2014). Safety of antipsychotic drugs: Focus on therapeutic and adverse effects. Expert Opin Drug Saf 13, 1031-1042.
90. Werner S, Malaspina D, and Rabinowitz J. (2007). Socio-economic status at birth is associated with risk of schizophrenia: Population-based multilevel study. Schizophr Bull 33, 1373-1378.
91. Woodruff PW, McManus IC, and David AS. (1995). Meta-analysis of corpus callosum size in schizophrenia. J Neurol Neurosurg Psychiatry 58, 457-461.
92. Yildiz M, Borgwardt SJ, and Berger GE. (2011). Parietal lobes in schizophrenia: Do they matter? Schizophr Res Treatment 2011, 581686.
93. Yu H, Bi W, Liu C, Zhao Y, Zhang JF2, Zhang D, and Yue W. (2014). Protein-interaction-network-based analysis for genome-wide association analysis of schizophrenia in Han Chinese population. J Psychiatr Res 50, 73-78.
94. Zhou SY, Suzuki M, Takahashi T, et al. (2007). Parietal lobe volume deficits in schizophrenia spectrum disorders. Schizophrenia Res 89, 35-48.